; (3) in subsection (k), by adding at the end the following: (4) Use of gene synthesis products and gene synthesis equipment by Federal agencies Not later than January 1, 2026, the Secretary shall report to the appropriate committees of Congress a description of the policies and procedures adopted by all agencies that fund or conduct life sciences research involving gene synthesis products or gene synthesis equipment to comply with this section. ; (4) in subsection (l)— (A) by redesignating paragraphs (2), (3), (4), (5), (6), (7), and (8) as paragraphs (5), (6), (8), (9), (10), (11), and (12), respectively; (B) by inserting after paragraph (1) the following: (2) The term gene synthesis equipment means equipment that can produce gene synthesis product, regardless of the technical mechanism by which such equipment works. (3) The term gene synthesis product — (A) means custom single-stranded or double-stranded DNA, or single-stranded or double-stranded RNA, which has been chemically or enzymatically synthesized or otherwise manufactured de novo and is of a length exceeding the screening threshold; and (B) does not include— (i) base chemical subunits, such as individual nucleotides or nucleosides, or oligonucleotides shorter than the screening threshold typically used as polymerase chain reaction primers; (ii) byproducts generated during sequencing that are not useful for assembly or cloning, as determined by the Secretary; or (iii) products generated from cloning or assembling of existing gene or gene fragment material, in circumstances in which the gene synthesis provider has no access or notice to the sequence design, as determined by the Secretary. (4) The term gene synthesis provider — (A) means— (i) an entity that creates gene synthesis product for delivery to a customer in the United States; or (ii) a distributor of gene synthesis product in the United States, including an entity that manufactures gene synthesis product for use by another party, whether such other party is inside and outside of the entity